Michael Cloonan, CEO of Sionna Therapeutics, shares his insights about leadership in biopharma and how Sionna is working to restore the cystic fibrosis transmembrane conductance regulator for people living with cystic fibrosis.

Erik van den Berg, CEO of Memo Therapeutics, shares his insights about leadership in biopharma and how Memo is working to develop antibodies to transform the lives of patients with viral infections and cancer.

“What leads a leader?”

As you listen to clips from BioBoss podcasts, you may hear remarkably consistent ideas about leadership, as shared by BioBoss guests, who reflect on their younger years and how those experiences shaped their desire, and ability to lead.  

BioBoss podcast host John Simboli reflects on Seasons 1-6 and invites listeners to Season 7 starting in January 2025

Sam Clark, founder and CEO of Terran Biosciences, shares his insights with BioBoss host John Simboli about leadership in biopharma and how Terran is working to develop therapeutics and technologies for patients with neurological and psychiatric diseases. 

Iain Kilty, CEO of Sitryx, shares his insights about leadership in biopharma and how Sitryx is working to alter immune cell metabolism to resolve disease

Steve Uden, co-founder and CEO of RallyBio, shares his insights about leadership in biopharma and how Rallybio is working to to profoundly  change the odds for patients living with rare diseases.

Karine Rossignol, co-founder and CEO of Smart Immune, shares her insights with BioBoss host John Simboli about leadership in biopharma and how Smart Immune is working to harness a patient's own thymus to re-arm the immune system against cancer and infection.

Erik Buntinx, founder and CEO of ANeuroTech, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how ANeurotech is working to develop effective treatments, with minimal or no side-effects, for patients who suffer with depression

Helen Torley, CEO of Halozyme Therapeutics, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how Halozyme is working to reinvent the patient experience by easing the burden of treatment and improving patient outcomes.

James Graham, CEO of Recce Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Recce is working to develop a new class of synthetic anti-infectives designed to address the threat of antibiotic-resistant superbugs.

Mike Gaffney, CEO of Cellphire Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Cellphire is working to save lives by bringing novel hemostatic products to patients in need.

Bruce Leuchter, CEO of Neurvati Neurosciences, shares his insights about leadership in biopharma and how Neurvati is working to advance drugs with the potential to improve the health and lives of people living with neurological and psychiatric disorders.

David Barmam, founder and CEO of Emendio Biotherapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Emendo is working to evolve traditional CRISPR tools and create new nucleases customized to any genetic disease.

BioBoss podcast host John Simboli reflects on Seasons 1-5 and invites listeners to Season 6 starting in January 2024

Anat Binur, co-founder and CEO of Ukko, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how Ukko is working to improve the lives of people who suffer from food allergies.

Markku Jalkanen, founder and CEO of Faron Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Faron is working to develop new immunotherapies to address unmet medical needs in cancer and improve patient lives.

Lisa Deschamps, CEO of AviadoBio, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how AviadoBio is working to develop transformative medicines for patients living with debilitating and life-threatening neurodegenerative disorders.

Leonard Mazur, founder and CEO of Citius Pharmaceuticals, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Citius is working to unlock the potential of first-in-class critical care therapeutics, with a pipeline of anti-infectives in oncology, adjunct cancer care and stem cell therapy.

Dario Neri, co-founder and CEO of Philogen, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Philogen is working to discover and develop targeted therapies to treat cancer and chronic inflammation.

Naseem Amin,  CEO of Orphalan, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Orphalan is working to transform rare disease treatment.

Hartmut Ehrlich,  CEO of Abivax, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Abivax is working to develop treatments modulating the body’s natural immune system to treat patients with chronic inflammatory diseases, viral infections and cancer.

Ivo Timmermans, co-founder and  CEO of Pleco Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Pleco is working to develop breakthrough therapies that change the balance in the treatment of cancer.

Todd Harris, CEO of Tyra Biosciences, shares his insights about leadership in biopharma and how Tyra is working to develop precision medicines that target large fibroblast growth factor receptor biology.

Philipp Spycher, co-founder and  CEO of Araris Biotech, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Araris is working to develop a linker technology for antibody-drug conjugates that enables attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Pat Arensdorf, founder and  CEO of Exai Bio, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Exai is working to develop a next-generation RNA-based platform to deliver actionable insight into cancer biology from a simple blood draw.

Josh Geballe, Managing Director of Yale Ventures, shares his thoughts with BioBoss host John Simboli about leadership and community building in biopharma. Yale Ventures is a new initiative created by Yale University to support and expand innovation and entrepreneurship across Yale university and throughout the greater New Haven region with the goal of helping to develop innovations that impact the world's greatest challenges.

BioBoss podcast host John Simboli reflects on the success of seasons 1, 2 ,3 and 4 and welcomes listeners to listen in on his conversations about leadership with biopharma founders and CEOs in  BioBoss season 5.

John is delighted to open BioBoss season 5 with his conversation with Josh Geballe, Managing Director of Yale Ventures, who shares his thoughts about leadership, innovation, entrepreneurship and community building in biopharma and biotech. Yale Ventures is a new initiative created by Yale University to support and expand innovation and entrepreneurship across Yale university and throughout the greater New Haven region with the goal of helping to develop innovations that impact the world's greatest challenges.

Luca Benatti,  CEO of EryDel, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how EryDel is working to develop specialized therapies for the treatment of rare diseases by using the patient’s own blood.

Elisabet de los Pinos, founder and CEO of Aura Biosciences, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how Aura is working to envision new ways to treat cancer.

Paul Radspinner, founder and CEO of Flugen, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Flugen is working to develop a more effective vaccine in the fight against influenza and respiratory disease.

Jesús Martin-Garcia, CEO of GeNeuro, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Geneuro is working to develop treatments against neurological disorders and autoimmune diseases by neutralizing causal factors encoded by Human Endogenous Retroviruses.

Cliff Stocks, founder and CEO of OncoResponse speaks with BioBoss host John Simboli. Hear Cliff’s insights about leadership in biopharma and how OncoResponse is working to identify fully human monoclonal antibodies as therapeutics for the treatment of cancer.

Brian Finrow, Co-founder and CEO of Lumen Bioscience, speaks with BioBoss host and biopharma branding veteran John Simboli. Hear Brian’s thoughts about leadership and how Lumen Biosciences is working to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology. 

Eduardo Bravo, CEO of Citryll, shares his insights about leadership in biopharma and how Citryll is working to transform the approach to treating immune mediated inflammatory diseases.

BioBoss host John Simboli speaks with Alex Blyth,  founder and CEO of LifT BioSciences.

Hear Andrew speak with BioBoss host John Simboli about leadership in biopharma and how IMV is working on advancing a portfolio of therapies based on the Company’s immune-educating platform.

Kevin Lee, CEO of Bicycle Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Bicycle Therapeutics is working on developing a new class of medicines, called Bicycles, for diseases that are underserved by existing therapeutics. 

BioBoss host John Simboli speaks with Reenie McCarthy, CEO of Stealth BioTherapeutics, headquartered in Needham, MA.. Hear Reenie's thoughts about leadership in biopharma and how Stealth Biotherapeutics is working on developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases.

BioBoss host John Simboli speaks with Yochi Slonim, founder and CEO of Anima Biotech, headquartered in Boston with R&D in Tel Aviv.. Hear Yochi's thoughts about leadership in biopharma and how Anima Biotech is working on a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against undruggable proteins.

BioBoss host John Simboli speaks with Clive Richardson, CEO of Akari Therapeutics, headquartered in London with offices in New York. Hear Clive's thoughts about leadership in biopharma and how Akari Therapeutics  is working to develop life-transforming treatments for autoinflammatory diseases involving the complement and leukotriene  pathways

BioBoss podcast host John Simboli reflects on the success of seasons 1, 2 and 3 and welcomes listeners to listen in on his conversations about leadership with biopharma founders and CEOs in  BioBoss season 4.

BioBoss host John Simboli speaks with Stefan König , CEO of George Medicines, headquartered in London. Hear Stefan’s thoughts about leadership in biopharma and how George Medicines is working to extend and improve the lives of people suffering from the world’s leading causes of death and disability—including hypertension, cardiovascular disease and type 2 diabetes

Derek Maetzold, CEO of Castle Biosciences shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Castle is leveraging its expertise in cancer genomics and the use of artificial intelligence to improve patient outcomes.

Bob Cobuzzi, Chief Executive Officer of Diffusion Pharmaceuticals,speaks with BioBoss John Simboli about leadership and how Diffusion Pharmaceuticals is working to develop novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most.

Abbas Kazimi, CEO of Nimbus Therapeutics, shares his insights about leadership in biopharma and how Nimbus is working to design and develop small molecule medicines capable of improving patients' lives.

Panna Sharma, CEO of Lantern Pharma, headquartered in Dallas, Texas, shares his thoughts with BioBoss host John Simboli about leadership and how Lantern is working at the intersection of artificial intelligence, genomics and machine learning to advance precision oncology therapies.

Nandan Padukone, CEO of IM Therapeutics, headquartered in Woburn, Massachusetts, shares his thoughts with BioBoss host John Simboli about leadership and how IM Therapeutics is targeting the root cause of autoimmunity with therapeutic design directed at human leukocyte antigens.

"I think I've always found motivation from being able to take a highly technical topic and dig in. I'm never the person that knows most about the topic. But I strive to be like the person who knows third or fourth most about whatever topic is going." 

– Mathew Gline: CEO of Roivant Sciences

Koen De Witte, managing director of reMYND NV, headquartered in Leuven, Belgium, shares his thoughts with BioBoss host John Simboli about leadership and how reMYND is advancing treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction.